FY2027 Earnings Estimate for C4 Therapeutics, Inc. (NASDAQ:CCCC) Issued By Brookline Capital Management

C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Stock analysts at Brookline Capital Management increased their FY2027 earnings estimates for C4 Therapeutics in a research report issued to clients and investors on Wednesday, May 8th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of $15.91 for the year, up from their previous estimate of $15.44. The consensus estimate for C4 Therapeutics' current full-year earnings is ($1.86) per share. Brookline Capital Management also issued estimates for C4 Therapeutics' FY2028 earnings at $47.49 EPS.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.01). The company had revenue of $3.26 million during the quarter, compared to the consensus estimate of $5.23 million. C4 Therapeutics had a negative net margin of 638.34% and a negative return on equity of 55.30%.

Several other research firms have also recently weighed in on CCCC. Stifel Nicolaus boosted their price target on shares of C4 Therapeutics from $13.00 to $14.00 and gave the stock a "buy" rating in a report on Thursday. Wells Fargo & Company boosted their price target on shares of C4 Therapeutics from $7.00 to $8.00 and gave the company an "equal weight" rating in a research report on Thursday. JPMorgan Chase & Co. raised shares of C4 Therapeutics from an "underweight" rating to a "neutral" rating and set a $6.00 target price on the stock in a report on Monday, January 29th. Finally, Morgan Stanley upped their target price on shares of C4 Therapeutics to $8.00 and gave the stock an "equal weight" rating in a report on Monday, February 26th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $10.11.

C4 Therapeutics Stock Down 9.4 %

C4 Therapeutics stock traded down $0.64 during midday trading on Friday, hitting $6.16. 1,457,321 shares of the stock were exchanged, compared to its average volume of 3,320,010. C4 Therapeutics has a 52-week low of $1.06 and a 52-week high of $11.88. The stock has a market capitalization of $423.87 million, a price-to-earnings ratio of -2.31 and a beta of 3.22. The business's 50-day moving average price is $8.04 and its 200-day moving average price is $5.75.

Institutional Investors Weigh In On C4 Therapeutics

Several institutional investors have recently added to or reduced their stakes in CCCC. Tower Research Capital LLC TRC raised its stake in C4 Therapeutics by 33.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 16,322 shares of the company's stock valued at $92,000 after buying an additional 4,063 shares during the last quarter. Headlands Technologies LLC purchased a new stake in C4 Therapeutics during the 4th quarter valued at $39,000. Raymond James & Associates raised its stake in C4 Therapeutics by 8.5% during the 3rd quarter. Raymond James & Associates now owns 91,380 shares of the company's stock valued at $170,000 after buying an additional 7,146 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in C4 Therapeutics during the 4th quarter valued at $49,000. Finally, Barclays PLC raised its stake in C4 Therapeutics by 30.7% during the 3rd quarter. Barclays PLC now owns 43,614 shares of the company's stock valued at $81,000 after buying an additional 10,246 shares during the last quarter. Hedge funds and other institutional investors own 78.81% of the company's stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.